Streetbeat News

Regulatory

CYBN

Cybin Inc. (NYSE:CYBN) has completed enrollment in its Phase 2 study of CYB003, a treatment for major depressive disorder. The company has reported no serious adverse events and a favorable safety profile. Cybin plans to scale the CYB003 program to a potential Phase 3 study in early 2024. The program is supported by a recently granted U.S. patent and the company anticipates potential Breakthrough Therapy designation, subject to FDA approval, in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:32 am

SNSE

Sensei Biotherapeutics presented new preclinical data at the Seventh Cri-enci-aacr International Cancer Immunotherapy Conference, reinforcing the pharmacokinetic profile, safety characteristics, and mechanism of action of SNS-101. The data from a multi-dose GLP toxicology study in cynomolgus monkeys supports the exceptional PK and safety profile of SNS-101. Mechanistic mouse data shows SNS-101 drives tumor macrophages to adopt an immunostimulatory, anti-tumor phenotype.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:30 am

FXI

China's Premier Li has stated that the country's economy is at a major juncture of high-quality development and overcoming challenges. He emphasized the need for more precise and effective policies in response to enterprises' demands for financing support and tax incentives.

Portfolio Pulse from Charles Gross

September 21, 2023 | 11:18 am

A

ABT

BDX

The Biden administration has announced that it will restart the distribution of free at-home COVID-19 tests to American households. The U.S. Department of Health and Human Services (HHS) plans to distribute these tests, which can identify current COVID variants, starting next Monday. HHS has also invested $600 million in 12 domestic COVID-19 test manufacturers, expecting to secure approximately 200 million tests from these companies.

Portfolio Pulse from Vandana Singh

September 21, 2023 | 11:16 am

EWU

The U.K. has decided to keep its interest rate unchanged at 5.25%, against an estimated 5.50%.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:10 am

EVGN

Evogene has received a Nasdaq minimum bid price notification, indicating that its stock price has fallen below the minimum required for continued listing.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:09 am

MDT

Medtronic Diabetes has received CE Mark for its new Simplera CGM, which is 50% smaller than its previous generation and offers a simple insertion and improved user experience.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:04 am

TRDA

Entrada Therapeutics has announced the dosing of its first participant in a Phase 1 clinical trial for ENTR-601-44, a potential treatment for Duchenne Muscular Dystrophy. The company expects to have data from the trial in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:01 am

DIA

QQQ

SPY

Following the Federal Reserve's decision to keep the federal funds rate between 5.25% and 5.5%, US and global markets experienced declines. Most S&P 500 sectors, the Dow Jones Industrial Average, the Nasdaq Composite, and Asian markets including Japan's Nikkei 225, Australia's S&P/ASX 200, China's Shanghai Composite, and Hong Kong's Hang Seng Stock Exchange all closed lower. European markets and commodities also traded lower, while US futures and the U.S. Dollar Index were down.

Portfolio Pulse from Akanksha Bakshi

September 21, 2023 | 10:46 am

EWU

IMMP

VGK

Immutep Limited has received regulatory authorization for the use of eftilagimod alpha, manufactured at a commercial 2,000L scale, in clinical trials across multiple European countries. The countries include Germany, Belgium, Denmark, and the United Kingdom.

Portfolio Pulse from Charles Gross

September 21, 2023 | 10:09 am